The capsule drug device: Novel approach for drug delivery to the eye

Vision Research

Volumn 50, Issue 7, 2010, Pages 680-685

  Molokhia, Sarah A ^a   Sant, Himanshu ^b   Simonis, Jacquelyn ^a   Bishop, C J ^b   Burr, R M ^b   Gale, Bruce K ^b   Ambati, Balamurali K ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Age macular degeneration; Drug delivery; Implant; Pharmacokinetics; Polymethylmethacrylate; Semi permeable membrane

Indexed keywords

BEVACIZUMAB; POLY(METHYL METHACRYLATE); POLYVINYL ALCOHOL; SILICONE;

ARTICLE; CATARACT EXTRACTION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG STABILITY; EQUIPMENT DESIGN; FEASIBILITY STUDY; IN VITRO STUDY; LENS CAPSULE; LENS IMPLANT; MEMBRANE COMPONENT; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TEMPERATURE DEPENDENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; MACULAR DEGENERATION; MATERIALS TESTING; PERMEABILITY;

EID: 77950517318     PISSN: 00426989     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.visres.2009.10.013     Document Type: Article

References (19)

1. Arimura N., Otsuka H., Yamakiri K., Sonoda Y., Nakao S., Noda Y., et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009, 116(5):921-926.
2. Balkrishnan R., Bond J.B., Byerly W.G., Camacho F.T., Anderson R.T. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization. The American Journal of Geriatric Pharmacotherapy 2003, 1(2):75-81.
3. Baynes B.M., Trout B.L. Rational design of solution additives for the prevention of protein aggregation. Biophysical Journal 2004, 87(3):1631-1639.
4. Beutel J., Ziemssen F., Luke M., Partsch M., Bartz-Schmidt K.U., Gelisken F. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: One-year results. International Ophthalmology 2008.
5. Brumm M.V., Nguyen Q.D. Fluocinolone acetonide intravitreal sustained release device-A new addition to the armamentarium of uveitic management. International Journal of Nanomedicine 2007, 2(1):55-64.
6. Cantor C.R., Shimmel P.R. Biophysical chemistry: Part II: Techniques for the study of biological structure and function 1980, W.H. Freeman.
7. Cleland J.L., Powell M.F., Shire S.J. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Critical Reviews in Therapeutic Drug Carrier Systems 1993, 10:307-377.
8. Congdon N., O'Colmain B., Klaver C.C., Klein R., Munoz B., Friedman D.S., Kempen J., Taylor H.R., Mitchell P. Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology 2004, 122(4):477-485.
9. Geroski D.H., Edelhauser H.F. Drug delivery for posterior segment eye disease. Investigative Ophthalmology & Visual Science 2000, 41(5):961-964.
10. Grover D., Li T.J., Chong C.C. Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews 2008, (1):CD005656.
11. Iturralde D., Spaide R.F., Meyerle C.B., Klancnik J.M., Yannuzzi L.A., Fisher Y.L., Sorenson J., Slakter J.S., Freund K.B., Cooney M., Fine H.F. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 2006, 26(3):279-284.
12. Koch F.H., Gumbel H.O., Hattenbach L.O., Ohrloff C. Intravitreal endoscopic visualization of intraocular ganciclovir devices: Improved long-term treatment of CMV retinitis. Klinische Monatsblatter Fur Augenheilkunde 1999, 214(2):107-111.
13. Lang J.C. Ocular drug delivery: Conventional ocular formulations. Advanced Drug Delivery Reviews 1995, 16:39-43.
14. Lee P.P., Levin L.A., Walt J.G., Chiang T., Katz L.M., Dolgitser M., Doyle J.J., Stern L.S. Cost of patients with primary open-angle glaucoma: A retrospective study of commercial insurance claims data. Ophthalmology 2007, 114(7):1241-1247.
15. Lo R., Li P.Y., Saati S., Agrawal R., Humayun M.S., Meng E. A refillable microfabricated drug delivery device for treatment of ocular diseases. Lab on a Chip 2008, 8(7):1027-1030.
16. Sieving P.A., Caruso R.C., Tao W., Coleman H.R., Thompson D.J., Fullmer K.R., Bush R.A. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(10):3896-3901.
17. Subramanian M.L., Ness L., Abedi G., Ahmed E., Daly M., Feinberg E., Bhatia S., Patel P., Nguyen M., Houranieh A. Bevacizumab vs Ranibizumab for age-macular degeneration: Early results of a prospective double-masked, randomized clinical trial. American Journal of Ophthalmology 2009, 9:9.
18. Urtti A., Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Survey of Ophthalmology 1993, 37(6):435-456.
19. Yao T.J., Yang X., Tai Y.C. Sensors and Actuators A 2002, 97:771-775.